We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Urinary Epidermal Growth Factor Investigated for Diabetes Nephropathy

By LabMedica International staff writers
Posted on 06 Aug 2021
Print article
The Invitrogen Human EGF ELISA Kit measures levels of epidermal growth factor (EGF) in human serum, plasma, and cell culture supernatant using 96-well plates (Photo courtesy of Thermo Fisher Scientific)
The Invitrogen Human EGF ELISA Kit measures levels of epidermal growth factor (EGF) in human serum, plasma, and cell culture supernatant using 96-well plates (Photo courtesy of Thermo Fisher Scientific)
Type 1 diabetes mellitus is an auto-immune metabolic disease with chronic hyperglycemia. For many patients with type 1 diabetes (T1DM), it is challenging to maintain near-normal glucose blood levels and to reduce the risk of both acute (hypoglycemia, ketoacidosis) and chronic microvascular (retinopathy, neuropathy and nephropathy) and macrovascular complications.

Epidermal growth factor (EGF) stimulates cell growth, proliferation and differentiation by binding to its receptor EGFR. In the kidney, EGF is involved in the repairing process of kidney structures. EGF is synthetized along the kidney tubules and excreted into the urine, making urinary EGF a potential hallmark for regenerative functional capacity of the tubulointerstitial compartment of the kidney.

Pediatric Nephrologists at the University of Antwerp (Antwerp, Belgium) and their colleagues included in a study 158 children with type 1 diabetes mellitus and 40 healthy controls. Serum and urine samples were collected three times with an interval of at least one month to determine creatinine (serum and urine), epidermal growth factor and albumin (urine).

The team explored whether urinary epidermal growth factor (uEGF) might serve as an early marker of diabetes nephropathy compared to microalbuminuria in children and adolescents. Urinary EGF was measured using an EGF human Elisa kit (Invitrogen, Waltham, MA, USA). The detection limit of this assay was 3.9 pg/mL. For the comparative analysis in children and adolescents, the scientists corrected the values accounting for growth. Serum and urine creatinine, urine total protein and microalbuminuria were analyzed with the Dimension Vista system (Siemens Healthcare Diagnostics, Deerfield, MA, USA).

The investigators reported that urinary EGF was significantly lower in T1DM compared to healthy children. In children with T1DM, the mean duration of diabetes was 5.49 ± 3.29 years with a mean HbA1c of 7.7 ± 1.0% (60 ± 11 mmol/mol) and a mean insulin need of 0.87 ± 0.20 units/kg/day. Forty-four children (27.8%) were younger than six years when T1DM was diagnosed. A relatively lower glomerular filtration rate (eGFR) was associated with a decreased uEGF. The uEGF was independently associated with eGFR in a multivariate analysis. None of the patients with an eGFR < 90 mL/min/1.73 m2 had microalbuminuria > 30 mg/g creatinine, while 9.5% and 10.1% of the patients with an eGFR 90–110 mL/min/1.73 m2 and > 110 mL/min/1.73 m2 respectively did have microalbuminuria > 30 mg/g creatinine.

The authors concluded that uEGF is a promising ‘next generation’ biomarker associated with early signs of diabetes nephropathy in children and adolescents and worth further investigation as a single biomarker or as one of a multi-biomarker panel. The study was published on July 7, 2021 in the journal Diabetes Research and Clinical Practice.

Related Links:

University of Antwerp
Invitrogen
Siemens Healthcare Diagnostics 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more